# StableVisc™

1.0% sodium hyaluronate




# Next-generation protection. Complete support.

StableVisc™ with sorbitol is the only cohesive OVD in the US offering next-generation mechanical and chemical protection.

### ENHANCED FREE RADICAL PROTECTION

- StableVisc™ with 4% sorbitol not only forms a strong mechanical barrier but also delivers chemical protection from free radicals[1]

### COHESION AND CONTROL

- In a wet lab survey, six leading cataract surgeons rated StableVisc™ superior in ease of removal, maintaining chamber stability, anterior chamber distribution, and visco-dissection, compared to ProVisc®[1]

### LARGE FILL VOLUME

- StableVisc™ leads the US cohesive OVD market in fill volume at 1 mL (compared to 0.85 mL for EndoCoat® and 0.40 mL, 0.55 mL, or 0.85 mL for ProVisc®)

FREE RADICALS IN CATARACT SURGERY/SORBITOL PROTECTION/COHESION/CONTROL

© 2024 Bausch + Lomb. STV.0001.USA.24

BAUSCH+LOMB

# StableVisc™ Safety Profile

In an FDA clinical study, StableVisc™ was significantly noninferior to ProVisc® in the proportion of patients with postoperative IOP ≥ 30 mmHg at any follow-up visit. 5.2% for StableVisc™ and 8.2% for ProVisc®.[1,a]

[a]Primary safety variable: postoperative IOP







Reference:
Packer M, Shultz M, Loden J, Lau G. Safety and effectiveness comparison of a new cohesive ophthalmic viscosurgical device. *J Cataract Refract Surg.* 2023;49(8):804-811.

Set up your StableVisc™ trial

## Indications and Important Safety Information for ClearVisc™, StableVisc™ and TotalVisc™ OVDs

### INDICATIONS FOR USE

ClearVisc, StableVisc and TotalVisc OVDs are indicated for use as surgical aids in ophthalmic anterior segment procedures including: Extraction of a cataract; Implantation of an intraocular lens (IOL)

### CONTRAINDICATIONS

There are no contraindications to the use of ClearVisc, StableVisc and TotalVisc when used as a surgical aid in ophthalmic anterior segment procedures.

### PRECAUTIONS

Precautions normally considered during anterior segment procedures are recommended. Pre-existing glaucoma may place patients at risk for increases in intraocular pressure from the OVD during the early postoperative period.

### WARNINGS

- Do not use if the sterile barrier has been breached. Sterility cannot be guaranteed, and the patient will be at increased risk for infection.
- Do not use the OVD in subjects with known allergies to any of its components.
- An excess quantity of OVD should not be used. Excess OVD can cause increased intraocular pressure.
- The OVD should be removed from the anterior chamber at the end of surgery to prevent or minimize postoperative intraocular pressure increases (spikes). OVD remaining in the eye can cause increased intraocular pressure.
- If the postoperative intraocular pressure increases above expected values, corrective therapy should be administered. Increased intraocular pressure may lead to inflammation or vision loss.
- Do not re-use the cannula. Even after cleaning and rinsing, resterilized cannula could release particulate matter as the OVD is injected. It is recommended that a single-use disposable cannula be used when administering the OVD. Reuse may cause eye inflammation.
- If any particulate matter is observed, it should be removed by irrigation and/or aspiration. Particulate matter left in the eye may cause increased IOP or Light scattering/obstruction.
- Store at 2° to 8°C (36° to 46°F). Protect from freezing. The shelf life of ClearVisc, StableVisc and TotalVisc is not guaranteed if it is not properly stored.

### ADVERSE REACTIONS

Sodium hyaluronate is a natural component of tissues within the body and is generally well tolerated in human eyes. Transient postoperative inflammatory reactions and increases in intraocular pressure have been reported. Inflammation may result from increased intraocular pressure caused by use of the OVD. Intraocular inflammation, i.e., toxic anterior segment syndrome (TASS), has been attributed to OVDs. Furthermore, vision loss may be possible as a result of increased intraocular pressure and inflammation.

### ATTENTION

Refer to the Directions for Use labeling for a complete listing of indications, warnings and precautions, clinical trial information, etc.

### CAUTION

Federal (USA) law restricts this device to the sale by or on the order of a physician.

Learn more at bauschsurgical.com

© 2024 Bausch + Lomb. STV.0001.USA.24

BAUSCH + LOMB